DNA amplifications are important mechanisms for protooncogene activation. Comparative genomic hybridization (CGH) to metaphase chromosome preparations has revealed amplifications in 10-20% of B-cell lymphomas (B-NHL). We analysed a series of 16 aggressive nonHodgkin lymphomas by the new approach termed Matrix-CGH (M-CGH) using genomic DNA microarrays as hybridization target. For M-CGH, a dedicated B-cell lymphoma chip was constructed containing 496 genomic targets covering oncogenes, tumor suppressor genes as well as chromosome regions frequently altered in B-NHL. In 10 of 16 samples a total of 15 DNA amplifications were identified. The amplicons included BCL2, REL, CCND1, CCND2, JAK2, FGF4 and MDM2. Four of the 15 amplifications remained undetected by chromosomal CGH. The respective amplicons mapped to bands 2p13, 9p13-p21 and 12q24 and, were confirmed by fluorescence in situ hybridization. Furthermore, for four genomically amplified genes real-time quantitative reverse transcription polymerase chain reaction revealed elevated mRNA expression levels. These data show the superior diagnostic sensitivity of the newly developed diagnostic tool. As only a small portion of the genome (approximately 1.5%) has been analysed by the present DNA array, it is likely that gene amplifications are much more common in aggressive lymphomas than previously assumed.
DNA amplifications are important mechanisms for protooncogene activation. Comparative genomic hybridization (CGH) to metaphase chromosome preparations has revealed amplifications in 10-20% of B-cell lymphomas (B-NHL). We analysed a series of 16 aggressive nonHodgkin lymphomas by the new approach termed Matrix-CGH (M-CGH) using genomic DNA microarrays as hybridization target. For M-CGH, a dedicated B-cell lymphoma chip was constructed containing 496 genomic targets covering oncogenes, tumor suppressor genes as well as chromosome regions frequently altered in B-NHL. In 10 of 16 samples a total of 15 DNA amplifications were identified. The amplicons included BCL2, REL, CCND1, CCND2, JAK2, FGF4 and MDM2. Four of the 15 amplifications remained undetected by chromosomal CGH. The respective amplicons mapped to bands 2p13, 9p13-p21 and 12q24 and, were confirmed by fluorescence in situ hybridization. Furthermore, for four genomically amplified genes real-time quantitative reverse transcription polymerase chain reaction revealed elevated mRNA expression levels. These data show the superior diagnostic sensitivity of the newly developed diagnostic tool. As only a small portion of the genome (approximately 1.5%) has been analysed by the present DNA array, it is likely that gene amplifications are much more common in aggressive lymphomas than previously assumed. Oncogene (2003 Oncogene ( ) 22, 1425 Oncogene ( -1429 Oncogene ( . doi:10.1038 Keywords: CGH; microarray; gene amplification; lymphoma Amplification of genomic DNA is one of the molecular mechanisms that often leads to an increased expression of genes relevant for the initiation and progression of cancer cells. In many instances, gene amplifications are late events in tumorigenesis which have prognostic relevance, such as amplifications of MYCN in neuroblastomas or HER2 in breast cancer (Brodeur et al., 1984; Slamon et al., 1987) . In B-cell lymphomas (B-NHL), DNA amplifications have been identified in a significant proportion (10-20%) of cases (Werner et al., 1997; Knuutila et al., 1998; Rao et al., 1998) , mainly because of the introduction of comparative genomic hybridization (CGH) (Kallioniemi et al., 1992; Du Manoir et al., 1993) . However, the sensitivity of CGH is limited, because metaphase chromosomes are used as hybridization targets. Thus, for the detection of low copy number gains and losses, a minimum of 3-10 Mbp DNA need to be imbalanced (Bentz et al., 1998; Kirchhoff et al., 1999) . Recently, the principle of microarray-based comparative genomic hybridization (M-CGH) has been introduced (Solinas-Toldo et al., 1997; Pinkel et al., 1998; Pollack et al., 1999) . This technique provides a superior spatial resolution, allows a fully automated evaluation of experiments and a simultaneous analysis of hundreds of genomic loci (Snijders et al., 2001; Wessendorf et al., 2002) . In this study, we used a genomic microarray for the analysis of B-NHLs to assess the diagnostic potential for the detection of genomic amplifications. To evaluate the pathogenetic significance of the genomic data, mRNA expression levels of amplified genes were assessed using real-time quantitative reverse-transcription polymerase chain reaction (RQ-PCR).
A dedicated M-CGH chip consisting of 496 genomic DNA fragments immobilized on solid glass support was constructed for genome analysis in aggressive B-NHL (see Figure 1 ). To allow a marker-directed analysis, clones were selected according to their gene contents or their chromosomal mapping localizations. Multiple genes potentially involved in the pathogenesis of lymphoproliferative disorders (proto-oncogenes and cell cycle control genes, n ¼ 58; tumor suppressor genes, n ¼ 29) were covered by selected BAC and PAC clones (n ¼ 190) . A further set of clones mapped to critical regions identified in B-cell neoplasms by chromosomal banding analysis and CGH (n ¼ 68). A cluster of 215 clones linearly distributed across the genome at intervals of 15 Mbp was utilized to allow normalization in tumor specimens of unknown karyotype. Additional DNA-fragments from the X and Y chromosome were included to control performance of the experiment, and thus were excluded from the evaluation procedure. A detailed list of all target-DNAs can be found at http://www.dkfz-heidelberg.de/kompl_-genome/index.html. For the diagnosis of high-level amplifications, thresholds for ratio values were based on measurements of gender-specific signal ratio differences of X chromosomal DNA in samples of healthy human individuals. Simultaneous hybridizations of normal female versus normal male DNA were performed for 11 X-chromosomal DNA fragments. Each probe was spotted in replicas of 10 on the microarrays, and mean values and standard deviations were calculated from four independent hybridization experiments. The average signal ratio values for the X clones were: mean, 1.23; median, 1.24; standard deviation, 0.11. Based on these values for 2 : 1 copy number gains, a cutoff value of 1.6 (mean+3 standard deviation) was applied for specific amplicon detection.
Tumor tissue samples of 13 randomly selected diffuse large B-cell NHL (DLBCL) and 3 Burkitt lymphomas (BL) were screened for genomic alterations by M-CGH. These were classified according to the WHO classification of lymphoid neoplasms (Jaffe et al., 2001) . In seven of the 13 DLBCL cases a total of 10 amplified chromosomal loci were identified, whereas five amplified regions were detectable in BL. In four cases, multiple amplicons were found. Most frequent high-copy number gains affected chromosomal bands 18q21 (four cases), 12q12-q24 (four cases) and 9pl2-p24 (three cases). The ratio values for amplifications ranged from 1.64 to 16. A summary of the experimental data as well as information on gene or marker content is shown in Table 1 .
In 11 cases of DLBCL, sufficient RNA for gene expression analysis using RQ-PCR was available Figure 1 Example of a Matrix-CGH experiment. Image after hybridization of DNA derived from case DLBCL 1 (labeled in red; Cy5) versus human control DNA (labeled in green; Cy 3). Note the color differences in the magnified inset; the arrow indicates a DNA target containing the MDM2 gene on 12ql4 with an intensely red fluorescence signal after hybridization. By quantitative analysis, the fluorescence ratio was 2.38 indicating an amplification of this genomic region. The array consists of 496 BAC and PAC clones from libraries RPCIB753 (same as RP11) and RPCIP704 (same as RP19;3;4;5) (German Resource Center, Berlin) which were selected according to their gene content or their chromosomal mapping localization. Additional clones for certain genes (e.g. BCL2) were isolated by filter hybridizations. After DNA isolation according to standard protocols (Qiagen, Hildan, Germany), a sonification step (30 s) of all target DNAs was performed to reduce viscosity. Target DNAs (0.5 mg/ml in 3 Â SSC) were spotted in two identical arrays in replicas of 5 onto Poly-l-Lysin-coated glass slides using the omnigrid microarrayer (Gene Machines, San Carlos, CA). Finally, the slides were baked at 801C for 10 min and DNAs were crosslinked by UV light of 254 nm/240 mJ. After DNA isolation from cryopreserved tumor tissues, a dedicated PCR strategy was applied for universal amplification and fluorescence labeling of genomic DNA (Klein et al., 1999 ; modified according to Wessendorf et al., 2002) . For hybridization, l mg of labeled control DNA and l mg of differentially labeled tumor DNA were co-precipitated together with 60 mg of human Cot-1 DNA (Invitrogen, Karlsruhe, Germany) and resolved in 120 ml prewarmed Ultrahyb buffer (AMS Biotech, Abingdon, UK) at 371C for 30 min. After denaturation (751C for 5 min) and preannealing (60 min at 371C), hybridization was allowed for 36 h at 521C using a GeneTac s Hybridization chamber (Genomic Solutions, Huntingdon, UK). Slides were washed three times for 5 min in 50% formamide and 2 Â SSC, pH 7.0 at 421C. Additional washing in 0.1% SSC at 421C followed three times for 5 min. Slides were dehydrated in a series of 70, 90 and 100% ethanol. Images were acquired using a GenePixt 4000 A (Axon Instruments, Union City, CA) dual laser scanner in combination with GenePixt Pro 3.0 imaging software. For final evaluation, fluorescence ratios of two independent hybridization experiments were calculated and averaged using a dedicated M-CGH software (for details, see Wessendorf et al., 2002) (DLBCL: 1, 3, 4, 6-13). For selected genes with known or suspected pathogenetic relevance in B-NHL (BCL2, JAK2 and MDM2), gene expression levels were examined (see Table 2 ). Marked BCL2 mRNA overexpression was present in DLBCL 7 exhibiting genomic amplification of the BCL2 locus and DLBCL 9 carrying an IgH-BCL2 fusion (as assessed by PCR (Gribben et al., 1991) ). Similarly, in DLBCL 11 a BCL2 overexpression was observed. In this case, also a genomic amplification affecting chromosomal band 18q21 was indicated by distinct DNA targets in the M-CGH experiment. However, the respective ratio value for the specific target clone containing the BCL2 gene did not quite reach the threshold criteria (1.34).
Genomic amplification of the JAK2 tyrosine kinase gene was evident in DLBCL 10. Similarly to the BCL2 data, this case belonged to a tumor subset exhibiting a high expression of the respective JAK2 mRNA transcript. For the expression of the MDM2 gene, a striking correlation with MDM2 genomic amplification was found: DLBCL 1, which was the only case with genomic MDM2 amplification, had an elevated mRNA expression, whereas all other cases did not exhibit altered MDM2 expression levels.
By CGH to metaphase chromosomes, 11 DNA amplifications were found (six in DLBCL and five in BL). All amplifications detected by chromosomal CGH were also present using M-CGH, demonstrating the comprehensiveness of the clone set with regard to its diagnostic use in B-NHL. In addition, four amplifications were found in four different samples of DLBCL by M-CGH that were not detected using chromosomal CGH. These additional gains affected chromosomal bands 2pl3, 9pl3-p21 and 12q24 (see Figure 2) . For all metaphases of the respective cases, the quantitative CGH evaluation was carefully reviewed. The identification of the novel DNA amplifications was clearly due to a superior spatial resolution of the M-CGH assay and not due to limitations inherent to image analysis and ratio profile averaging of single metaphase chromosomes in CGH. DNAs from the BAC clones indicating hidden amplifications served as probes for subsequent interphase FISH experiments in the three cases of which sufficient cell material was available (nos. 1, 2 and 12). A FISH pattern typical of DNA amplification (clusters of multiple signals) was found in 50-70% of interphase nuclei (see Figure 2f ). In DLBCL 2, an amplicon was detected by BAC RP11-373L24 covering coding information for the v-rel reticuloendotheliosis viral oncogene homolog (REL) on chromosome band 2pl2-pl3. This gene has been found amplified in B-cell NHLs before (Houldsworth et al., 1996; Joos et al., 1996; Barth et al., 2001) . It is reported to be associated with tumor progression in aggressive B-NHL and may be associated with the recently identified 'germinal center' like subtype of DLBCL (Alizadeh et al., 2000; Rosenwald et al., 2002) . A novel amplicon was detected in DLBCL 12 on band 12q24 by RP11-608E13. This region contains RQ-PCR was performed as described previously by our group (Korz et al., 2002) . Briefly, total RNA was extracted using Trizol reagent (Gibco BRL, Eggenstein, Germany) and subsequent DNAse 1 digestion. cDNA synthesis was performed using the GeneAmp Kit (RNA PCR System; PE Applied Biosystems, Weiterstadt, Germany) with random hexamer primers. Quantitative assessment of cDNA amplification was detected through the dye SYBR green according to the manufacturer's manuals (PE Applied Biosystems). For thermal cycling procedures and specificity testing of the final PCR product see reference above. A calibration graph was obtained by serially diluted cDNA from the lymphoma cell line JVM. For normalization, two control amplicons of the housekeeping genes cyclophilin and laminin were used. For each displayed gene the sample specific value is compared to the median expression ratio of the remaining cases (in brackets) approximately 500 kbp between markers SHGC 153695 and SHGC 8063 (RP11-79E21 and RP11-462B18) covering the mRNA helicase RIG1, the aconitase gene ACO1 and at least three further predicted genes. RQ-PCR analysis displayed overexpression of the ACO1 mRNA in the respective tumor sample. Moreover, high expression levels of ACO1 were also measured in DLBCL 9 and 10. This may indicate a tumor associated dysregulation of iron homeostasis regulatory proteins in DLBCL.
In conclusion, we demonstrate the diagnostic utility of the newly developed genomic B-cell lymphoma chip for the detection of DNA amplifications. In contrast to chromosomal CGH, the array-based genome screening has a 20-100 fold higher resolution. This results in an increased sensitivity, indicated by the 15 amplicons detected in this series, four of which were not diagnosed using conventional CGH. Considering a 1.5% coverage of the human genome with the array presented here, it is highly probable that DNA amplifications in B-NHL are even more frequent. By broad application of M-CGH disclosure of many yet unknown imbalances in B-cell lymphomas can be envisioned.
